SCHEMBL20914141

SCHEMBL20914141

COc1cc(N)c(Cl)c2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(C#N)nn4c3=O)nc12

nearest known ligand 0.32

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 5/20 0.32
▸ MEN1 O00255 3/20 0.32
▸ KMT2A Q03164 3/20 0.32
▸ MAPT P10636 3/20 0.32
▸ MAT2A P31153 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ HTT P42858 4/20 0.31
▸ LMNA P02545 4/20 0.31
▸ KDM4E B2RXH2 3/20 0.31
▸ TP53 P04637 1/20 0.31
▸ DCTPP1 Q9H773 1/20 0.31
▸ HPGD P15428 4/20 0.30
▸ NPSR1 Q6W5P4 2/20 0.30
▸ ALDH1A1 P00352 3/20 0.30
▸ APAF1 O14727 1/20 0.30
▸ ADORA2A P29274 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ NOD2 Q9HC29 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914108 0.89 MAT2A (0.34) HSD17B10MEN1KMT2AMAPTMAT2A
SCHEMBL20914035 0.86 MAT2A (0.34) HSD17B10MEN1KMT2AMAPTMAT2A
SCHEMBL20914059 0.85 MAT2A (0.33) HSD17B10MEN1KMT2AMAPTMAT2A
SCHEMBL20913988 0.84 KMT2A (0.34) HSD17B10MEN1KMT2AMAPTHTT
SCHEMBL20913982 0.82 MAT2A (0.34) HSD17B10MEN1KMT2AMAT2AHTT
SCHEMBL20914077 0.81 TNKS (0.37) HSD17B10MEN1KMT2AMAPTMAT2A
SCHEMBL20837047 0.80 MAT2A (0.33) MEN1KMT2AMAT2AHTTHPGD
SCHEMBL20837240 0.80 KMT2A (0.34) HSD17B10MEN1KMT2AMAPTMAT2A
SCHEMBL20837038 0.80 ADORA2A (0.34) HSD17B10MEN1KMT2AMAT2AHTT
SCHEMBL20914018 0.79 MAT2A (0.34) HSD17B10MEN1KMT2AMAPTMAT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 HSD17B10 3047/4885MEN1 2785/4885KMT2A 3490/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 HSD17B10 3047/4885MEN1 2785/4885KMT2A 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback